OPK Opko Health Inc.

1.56
+0.03  (+2%)
Previous Close 1.53
Open 1.54
Price To Book 0.63
Market Cap 1,038,337,209
Shares 665,600,775
Volume 321,819
Short Ratio
Av. Daily Volume 5,750,033
Stock charts supplied by TradingView

NewsSee all news

  1. OPKO Health to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    MIAMI, Nov. 26, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) today announced that Company management will be participating in the 31st Annual Piper Jaffray Healthcare Conference being held December 3-5, 2019 at the

  2. Novitas Issues Final Local Coverage Determination for the 4Kscore® Test

    MIAMI, Nov. 15, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued its final Local Coverage Determination (LCD) for Medicare payments for the 4Kscore® test with

  3. OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results

    MIAMI, Nov. 05, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three months ended September 30, 2019. Business Highlights Somatrogon meets

  4. BioReference Laboratories and GeneDx to Present at NSGC 2019, Demonstrating Commitment to Genetic Counselors and the Research of Rare Genetic Disorders

    Elmwood Park, NJ, Nov. 04, 2019 (GLOBE NEWSWIRE) -- BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, and women's health division, GenPath, today

  5. OPKO Health to Report Third Quarter 2019 Financial Results on November 5, 2019

    MIAMI, Nov. 01, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report its operating and financial results for the three months ended September 30, 2019, as well as provide guidance on expected

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b top-line data March 21, 2019 met primary endpoint. Phase 3 trial planned.
OPK88003
Obesity and diabetes
Phase 2a trial planned for 2H 2018.
OPK88002
Pruritus in Stage 5 CKD patients undergoing dialysis
Phase 2a trial planned for 2H 2018.
OPK88001
Dravet Syndrome
Phase 2b trial to be initiated 2H 2017.
TT701 (selective androgen receptor modulator)
Benign Prostatic Hyperplasia (BPH)
Phase 2b trial suspension announced January 31, 2019.
OPK88004
Benign Prostatic Hyperplasia (BPH)
Phase 2 initial open label data due 1Q 2020.
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP
Adults - growth hormone deficiency
Phase 3 data met primary endpoint - October 21, 2019.
hGH-CTP
Children - growth hormone deficiency
Announced June 21 2016 FDA Approval
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4
Phase 2 ongoing as of September 2017.
Factor VIIa-CTP
Hemophilia
Phase 3 to be initiated 1H 2018.
Fermagate Tablets
hyperphosphatemia in CKD patients on chronic hemodialysis
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV

Latest News

  1. OPKO Health to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    MIAMI, Nov. 26, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) today announced that Company management will be participating in the 31st Annual Piper Jaffray Healthcare Conference being held December 3-5, 2019 at the

  2. Novitas Issues Final Local Coverage Determination for the 4Kscore® Test

    MIAMI, Nov. 15, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued its final Local Coverage Determination (LCD) for Medicare payments for the 4Kscore® test with

  3. OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results

    MIAMI, Nov. 05, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three months ended September 30, 2019. Business Highlights Somatrogon meets

  4. BioReference Laboratories and GeneDx to Present at NSGC 2019, Demonstrating Commitment to Genetic Counselors and the Research of Rare Genetic Disorders

    Elmwood Park, NJ, Nov. 04, 2019 (GLOBE NEWSWIRE) -- BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, and women's health division, GenPath, today

  5. OPKO Health to Report Third Quarter 2019 Financial Results on November 5, 2019

    MIAMI, Nov. 01, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report its operating and financial results for the three months ended September 30, 2019, as well as provide guidance on expected

  6. OPKO Health, Inc. Announces Pricing of its Offering of Common Stock

    MIAMI, Oct. 24, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. ("OPKO Health" or the "Company") (NASDAQ:OPK) today announced the pricing of an underwritten public offering of 50 million shares of its common stock (the

  7. OPKO Health, Inc. Announces Proposed Offering of Common Stock

    MIAMI, Oct. 22, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. ("OPKO Health" or the "Company") (NASDAQ:OPK) today announced that, subject to market and other conditions, it intends to offer and sell up to $100 million of

  8. OPKO Health Switches to Multichannel Veeva CRM to Drive More Effective Customer Engagement

    Veeva CRM empowers pharmaceutical field representatives with the right information they need to deliver a personalized customer experience Veeva Systems (NYSE:VEEV) today announced that OPKO Health (NASDAQ:OPK), a

  9. OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency

    MIAMI, Aug. 29, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that the last patient has completed the final visit in the Company's pivotal Phase 3 study evaluating the safety and efficacy of